D.E. Shaw & Co
MTNB icon

D.E. Shaw & Co’s Matinas BioPharma MTNB Stock Holding History

D.E. Shaw & Co’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-550
Closed -$24K – 3944
2019
Q2 		$24K Sell
550
-243
-31% -$11.7K ﹤0.01% 3613
2019
Q1 		$43K Sell
793
-89
-10% -$4.79K ﹤0.01% 3524
2018
Q4 		$26K Buy
+882
New +$34.6K ﹤0.01% 3701

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

D.E. Shaw & Co's MTNB Position: Q3 2019 in Review

D.E. Shaw & Co sold out of Matinas BioPharma (MTNB) in Q3 2019, closing a stake of 550 shares — an estimated $24K sold.

D.E. Shaw & Co first reported a position in MTNB in Q4 2018 and held it in 3 quarters. The position peaked at $43K in Q1 2019. 37 funds tracked by Wall St. Rank hold MTNB as of Q3 2019.

  • D.E. Shaw & Co reported no remaining Matinas BioPharma position as of Q3 2019 after selling out during the quarter.
  • D.E. Shaw & Co sold 550 Matinas BioPharma shares in Q3 2019, an estimated $24K.
  • D.E. Shaw & Co first reported a position in Matinas BioPharma in Q4 2018 and held it in 3 quarters.
  • D.E. Shaw & Co's Matinas BioPharma position peaked at $43K in Q1 2019.
  • 37 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2019.

Based on D.E. Shaw & Co's 13F filing for Q3 2019, filed 14 Nov 2019.